NBIX - NEUROCRINE BIOSCIENCES INC

130.22
-1.370   -1.052%

Share volume: 933,009
Last Updated: 04-21-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$131.59
-1.37
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
27%
Profitability 0%
Dept financing 38%
Liquidity 75%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.27%
1 Month
2.50%
3 Months
-5.20%
6 Months
-7.95%
1 Year
27.99%
2 Year
-2.57%
Key data
Stock price
$130.22
P/E Ratio 
29.55
DAY RANGE
$129.56 - $132.78
EPS 
$4.81
52 WEEK RANGE
$101.15 - $160.18
52 WEEK CHANGE
$26.16
MARKET CAP 
14.141 B
YIELD 
N/A
SHARES OUTSTANDING 
100.363 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-30-2025
BETA 
0.55
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,253,397
AVERAGE 30 VOLUME 
$1,131,831
Company detail
CEO: Kevin C. Gorman
Region: US
Website: neurocrine.com
Employees: 1,200
IPO year: 1996
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Neurocrine Biosciences, Inc. discovers, develops, markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. Company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease.

Recent news